A Study to Evaluate the Use of Pharmacogenomics in the Perioperative Period to Guide Drug Therapy in Patients Undergoing Total Knee Arthroscopy


About this study

The purpose of this study is to look at the use of pharmacogenomic data in the perioperative period to guide drug therapy in patients undergoing total knee arthroscopy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Patients 18 to 80
  • Patients undergoing primary total knee arthroplasty
  • Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures.

Exclusion Criteria

  • Patients with a current diagnosis of chronic pain
  • Patients requiring narcotics for greater than one week prior to surgery
  • Patients with chronic kidney disease with a pre-op creatinine greater than 1.5
  • Patient preference or need for spinal anesthesia rather than general anesthesia
  • Patient planned for robotic surgical approach

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Molly Kraus, M.D.

Closed for enrollment

Contact information:

Heather Crowe B.S.

(480) 342-4559


More information


Publications are currently not available

Mayo Clinic Footer